Merck R&D Exec Jumps To US FDA As Office Of New Drugs Deputy Director
Peter Stein, a leader in diabetes drug development programs, joins FDA as a new administration is about to come in; he fills one of 676 CDER vacancies.
You may also be interested in...
An industry veteran, Stein has been with agency for only two years; Bob Temple becomes powerful OND "consultant."
Peter Stein is a familiar face within OND and has been working alongside CDER Director Janet Woodcock on the proposed “modernization” of OND. As a previous recruit from outside FDA, Stein has had time to make the key connections and adjustments to working inside government.
Union of Concerned Scientists' survey finds 65% of 354 respondents feel their direct supervisors back them on politically contentious positions; Commissioner Gottlieb gets glowing reviews.